Results from AGMT_MM-1 published
In September, two publications on the AGMT_MM-1 study were published....
Prof. Richard Greil MD
Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Rebecca Dent MD FRCP (Canada)
Chair, Divison of Medical Oncology & Senior Consultant, National Cancer Center Singapore
Professor, Duke-NUS Medical School, Singapore
Dr. Denise Wolf PhD
Senior Bioinformatics Scientist, Department of Laboratory Medicine, University of California, San Francisco, CA, USA
Dr. Amrita Basu PhD
Assistant Professor, Department of Surgery, University of California, San Francisco, CA, USA
Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research, Lab Department of Molecular Biology, University of Salzburg, Cancer Cluster Salzburg (CCS), Salzburg, Austria
Assoc. Prof. Gabriel Rinnerthaler MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Luca Gianni MD
Chair, Breast Cancer Research Committee, Michelangelo Foundation, Milano, Italy
Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia
Prof. Pedro Romero MD
Deputy scientific managing director of the Lausanne Branch of the Ludwig Institute for Cancer Research, Department of Oncology, University of Lausanne, Switzerland
Prof. Alexander Egle MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Iosifina Foskolou
Department of Haematopoiesis, Sanquin, Amsterdam, NL and
Department of Physiology, Development and Neuroscience, Cambridge University, UK
Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany
Prof. Laurence Zitvogel MD PhD
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France, INSERM U1015, Villejuif, France
Berna Özdemir MD PhD
Department of Medical Oncology, Bern University Hospital and University of Bern, Switzerland
Priv.-Doz. Simon P. Gampenrieder MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Giuseppe Curigliano MD PhD
Professor of Medical Oncology, University of Milano, Head of Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
Prof. Dr. Niels Schaft PhD
Research group leader of the RNA-based Immunotherapy group, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
12:30 – 13:30 Welcome & Business Lunch
13:30 – 13:35 Introduction
Richard Greil, Salzburg
13:35 – 15:30 Clinical and Translational research
Chair: Richard Greil, Denise M. Wolf
Current evidence of immunotherapy in early breast cancer
Rebecca Dent (Singapore)
Predictive biomarkers for immunotherapy – findings from the I-SPY 2 trial
Denise M. Wolf (California)
Predictive factors for immune-related side effects
Amrita Basu (California)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
15:30 – 16:00 Coffee Break
16:00 – 18:30 Innate and adaptive Immune system
Fritz Aberger, Gabriel Rinnerthaler
Single-Cell spatial immune cell composition – findings from the NeoTRIPaPDL1 trial
Luca Gianni (Milano)
PD-L1 vs. TILs: analytic and diagnostic issues
Roberto Salgado (Antwerp)
Harnessing metabolic pathways to enhance antitumor immunity and immunotherapy
Pedro Romero (Lausanne)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
08:30 – 11:00 Metabolism & Immunogenicity
Chair: Pedro Romero, Alexander Egle
Hypoxia-inducible metabolites shape T cell fate
Iosifina Foskolou (Cambridge)
Immune escape in breast cancer and its therapeutic relevance
Barbara Seliger (Halle)
Influence on immunogenicity by the microbioma
Laurence Zitvogel (Paris)
Influence on immunogenicity by sex hormones
Berna C. Özdemir (Lausanne)
Panel-Discussion (focusing on immunogenicity)
All speakers
Moderator: Richard Greil (Salzburg)
11:00 – 11:30 Coffee break
11:30 – 13:00 New treatment strategies
Chair: Simon Gampenrieder, Niels Schaft
Immunotherapy strategies beyond PD1/PD-L1 inhibition
Giuseppe Curigliano (Milano)
CAR T-Cells in breast cancer
Niels Schaft (Erlangen)
Panel discussion
All speakers
Moderator: Richard Greil (Salzburg)
Closing Remarks
Richard Greil (Salzburg)
13:00 – 14:00 Business Lunch & Farewell
The registration form is now available, we look forward to your submission. We would like to point out that this conference is not open to the public. After your registration your entries will be checked by us, followed by information about your requested participation.
4th SALZBURG BREAST CANCER TALK – Mastering translational Immuno-Oncology has been accredited by the Diploma Continuing Education Program of the Austrian Medical Association (ÖÄK) for a maximum of 11 DFP points.
We have a new location for 2022:
Hotel Gersbergalm
Gersberg 37
5020 Salzburg
The hotel can be reached by car (sufficient parking available), by bus (line 151) or by cab (still city area).
Prof. Dr. Richard Greil
Dr. Simon P. Gampenrieder
Dr. Gabriel Rinnerthaler
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in Kooperation mit
Cancer Cluster Salzburg | www.cancercluster-salzburg.at
In September, two publications on the AGMT_MM-1 study were published....
01.- 02.03.2019 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
02.- 03.03.2018 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
10.- 11.02.2017 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...